Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers

Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-12-0962

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2013/07/24/1535-7163.MCT-12-0962.DC1.html

Cited Articles
This article cites by 41 articles, 20 of which you can access for free at:
http://mct.aacrjournals.org/content/12/10/2110.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1–Positive Breast Cancers

Erik A. Bey1, Kathryn E. Reinicke2, Melissa C. Srourgi3, Marie Varnes4, Vernon E. Anderson2, John J. Pink4, Long Shan Li5, Malina Patel6, Lifen Cao6, Zachary Moore6, Amy Rommel6, Michael Boatman1, Cheryl Lewis6, David M. Euhus6, William G. Bornmann7, Donald J. Buchsbaum6, Douglas R. Spitz8, Jinming Gao5, and David A. Boothman5

Abstract

Improving patient outcome by personalized therapy involves a thorough understanding of an agent’s mechanism of action. β-Lapachone (clinical forms, Arq501/Arq761) has been developed to exploit dramatic cancer-specific elevations in the phase II detoxifying enzyme NAD(P)H:quinone oxidoreductase (NQO1). NQO1 is dramatically elevated in solid cancers, including primary and metastatic [e.g., triple-negative (ER−, PR−, Her2/Neu−)] breast cancers. To define cellular factors that influence the efficacy of β-lapachone using knowledge of its mechanism of action, we confirmed that NQO1 was required for lethality and mediated a futile redox cycle where ~120 moles of superoxide were formed per mole of β-lapachone in 2 minutes. β-Lapachone induced reactive oxygen species (ROS), stimulated DNA single-strand break-dependent poly(ADP-ribose) polymerase-1 (PARP1) hyperactivation, caused dramatic loss of essential nucleotides (NAD+/ATP), and elicited programmed necrosis in breast cancer cells. Although PARP1 hyperactivation and NQO1 expression were major determinants of β-lapachone–induced lethality, alterations in catalase expression, including treatment with exogenous enzyme, caused marked cytotoxicity. Thus, catalase is an important resistance factor and highlights H2O2 as an obligate ROS for cell death from this agent. Exogenous superoxide dismutase enhanced catalase-induced cytoprotection. β-Lapachone–induced cell death included apoptosis-inducing factor (AIF) translocation from mitochondria to nuclei, TUNEL+ staining, atypical PARP1 cleavage, and glyceraldehyde 3-phosphate dehydrogenase S-nitrosylation, which were abrogated by catalase. We predict that the ratio of NQO1:catalase activities in breast cancer versus associated normal tissue are likely to be the major determinants affecting the therapeutic window of β-lapachone and other NQO1 bioactivatable drugs. Mol Cancer Ther; 12(10); 2110–20. ©2013 AACR.

Introduction

Approximately 1 in 8 women will be diagnosed with breast cancer in their lifetimes in the United States (1). Most current therapeutic strategies designed to treat breast cancer, as with other cancers, attack proliferative differences between tumor and associated normal breast tissue. These approaches frequently result in minimal efficacy, undesirable normal tissue toxicity, and often result in selection of drug resistant, aggressive cancer cells undergoing epithelial-to-mesenchymal transition, with increased metastatic potential (2–5). Because caspase pathways are commonly abrogated or altered in breast or other cancers (6), strategies for treating cycling, as well as dormant cancer cells, that exploit caspase-independent cell death pathways (e.g., programmed necrosis) are desperately needed. Few drugs mechanistically act to induce poly(ADP-ribose) polymerase-1 (PARP1)-mediated programmed necrosis in a tumor-specific manner and at clinically relevant doses (7). Most
agents known to stimulate PARP1-mediated programmed necrosis (e.g., N-methyl, N’-nitro, N-nitrosoguanidine (>5 mmol/L MNNG), or hydrogen peroxide (>200 μmol/L H₂O₂; refs. 8–10) do so at supra-lethal, nonachievable doses clinically. In contrast, β-lapachone (β-lap; see Fig. 1 for structure) stimulates PARP1 hyperactivation and causes dramatic intracellular nucleotide loss, particularly in NAD⁺ and ATP pools (10), at clinically achievable doses. PARP1 uses NAD⁺ as a substrate to conduct poly(ADP-ribosylation) (PAR) posttranslational modification of proteins, including itself, where poly(ADP-ribosylated)-PARP1 (PAR-PARP1) is functionally inactive.

β-Lap is efficacious against solid tumors that have endogenously overexpressed NAD(P)H:quinone oxidoreductase I (NQO1), including >80% non–small cell lung and pancreatic, as well as >60% prostate and >70% breast cancers, where 5- to >100-fold increases in NQO1 activities above adjacent normal tissue were reported (11–13). β-Lap undergoes an NQO1-dependent futile redox cycle (Fig. 1A), where >60 moles of NAD(P)H are consumed per mole β-lap in 1 to 2 minutes (12, 14–18). This futile cycle results from the instability of its hydroquinone and semiquinone forms, presumably consuming oxygen and theoretically creating dramatically elevated levels of superoxide (O₂⁻). Combined DNA damage and Ca²⁺ release from endoplasmic reticulum (Ca²⁺ER) stores culminates in PARP1 hyperactivation, NAD⁺/ATP loss, DNA repair inhibition, and programmed necrosis by unknown protein effectors (12, 16–19). The majority of reported cellular affects in β-lap–treated cancer cells are actually the result of dramatic NAD⁺/ATP losses (reviewed in ref. 20).

Understanding the role(s) of reactive oxygen species

![Figure 1.](image-url)

**Figure 1.** NQO1-dependent futile redox cycling of β-lap consumes O₂ and generates robust ROS. A, proposed futile redox cycle of β-lap in the presence of NQO1, where the hydroquinone form of β-lap is unstable. Through 2 one-electron oxidations, which presumably use O₂, the hydroquinone spontaneously reverts back to β-lap. This "bioactivatable redox cycle" of β-lap uses ≥60 moles NAD(P)H/mole β-lap in 2 minutes (15), consuming 2 moles O₂ per cycle, creating ~120 moles superoxide in 2 minutes. B (left), cell extracts from NQO1-expressing (231-NQ⁺) or NQO1–deficient (231-NQ⁻) MDA-MB-231 TNBC cells were placed in a closed system with 1, 2, or 15 μmol/L β-lap, ± dicoumarol (DIC), an NQO1 inhibitor, for 5 minutes. OCR was measured with an Ocean Optics O₂ sensor (left) as described in Materials and Methods. Each bar represents X-fold OCR means ± SE, of 2 independent experiments conducted in triplicate. **P ≤ 0.05 (1 vs. 2 μmol/L β-lap); *P ≤ 0.007 (15 μmol/L β-lap ± 40 μmol/L DIC). B (right), O₂ consumption rates and proton production rates were measured in mock-treated (control) or β-Lap 4 μmol/L exposed 231-NQ⁺ cells ± 40 μmol/L DIC using the Seahorse XF24 Analyzer and Assay Wizard software. Data represent means, percentage treated/control (T/C, %) ± SE from triplicate samples. C and D, β-Lap–treated 231-NQ⁺ and 231-NQ⁻ cells were analyzed for ROS formation at indicated times. Cells were stained with DHE (for O₂) in C, or DCFDA (H₂O₂) in D, and micrographs quantified as described (17) and in Materials and Methods. DOX (5 μmol/L, 30 minutes), H₂O₂ (200 μmol/L, 30 minutes) were used as positive controls. Student t tests were conducted to determine significance between means of treatment conditions conducted in triplicate, repeated 3 individual times.
(ROS) and ROS-scavenging enzymes in deterring the efficacy of β-lap or deoxyxynobiquone (DNQ), the only other NQO1 bioactivatable drug (7) against NQO1 over-expressed solid cancers remains unexplored.

Here, we report a potential mechanism of resistance to β-lap–induced cell death by catalase, potentiated by superoxide dismutase (SOD). PARP1 hyperactivation was the major determinant of downstream-programmed necrosis initiation when sublethal to lethal doses of β-lap were compared. Exposure of NQO1+ cells to sublethal β-lap doses (≤1 μmol/L) caused enhanced O2 consumption, ROS formation and single-strand breaks (SSBs); however, DNA lesions were below an apparent "threshold damage level" required for PARP1 hyperactivation. In contrast, lethal β-lap doses (≥2 μmol/L) that killed ≥50% NQO1+ MDA-MB-231 triple-negative breast cancer cells (TNBC, Supplemental Table S1) stimulated PARP1 hyperactivation causing dramatic NAD+/ATP losses. As a result, apoptosis inducing factor (AIF) activation and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) modification were noted that corresponded to programmed necrosis. Catalase spared β-lap–treated cells from H2O2 (but not O2•−) formation, PARP1 hyperactivation, AIF activation, atypical PARP1 and p53 proteolysis, blocked TUNEL+ staining, and enhanced clonogenic survival. The cytoprotective effects of catalase were enhanced by SOD co-addition, consistent with an obligate role of H2O2 in β-lap–induced lethality. Although inhibiting AIF expression slightly protected cells from β-lap–induced lethality, altering downstream protein effectors were much less effective than altering upstream processes, such as scavenging ROS or chelating Ca2+ in preventing lethality. The ratio of NQO1/catalase expression in tumor versus normal tissue may be a major determinant in the efficacy of antitumor regimen involving NQO1 bioactivatable drugs, such as β-lap.

Materials and Methods

Chemicals, reagents, and antibodies

β-Lap (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione; Fig. 1) was synthesized by us, confirmed by NMR, dissolved in DMSO at 50 μmol/L, and concentrations verified by spectrophotometry (15). Menadione and doxorubicin (DOX) were obtained from Sigma-Aldrich and dissolved in DMSO or PBS (DOX), respectively. Dicoumarol (DIC; Sigma-Aldrich) was used as described (15). 5-(and-6)Chloromethyl-2,7-dichlorodi-hydrofluorescein diacetate (DCFDA, 5 μmol/L) and dihydroethidium (DHE, 5 μmol/L) used to assess ROS formation were purchased from Invitrogen and used as described previously (18, 19). N-Acetyl-l-cysteine (NAC; Sigma-Aldrich) was used at 5 mmol/L for 24-hour pre-treatments and 2-hour cotreatments as described (21). Xanthine, nitroblue tetrazolium, diethylentriaminepentacetic acid, catalase, CuZnSOD, bovine serum albumin (BSA), bathocuproine disulfonic acid disodium salt hydrate, and xanthine oxidase (Sigma-Aldrich) were used as described (22). Staurosporine (STS) and the pan-caspase inhibitor, zVAD-FMK (Z-VAD), were obtained and used as described (refs. 12, 14–18; see structures, Supplemental Fig. S1). In transient AIF knockdown experiments, AIF (siAIF), NQO1 (si-NQ), and scrambled control vector (SCR) siRNAs were purchased from (Dharmacon).

Cell lines, cell culture, treatments, and survival

MDA-MB-231 TNBC cells lacking or expressing NQO1 and MCF-7-WS8 (MCF-7) cells were grown as described (15, 17). Additional breast cancer cell lines were purchased from ATCC, MAP-tested and were free of mycoplasma. Breast cancer cell lines were grown in RPMI 1640 media at 37°C in a humidified 10% CO2–95% air atmosphere. Human mammary epithelial cells (HMEC 1585) were isolated from normal human mammary epithelial tissue of a patient without breast cancer and subjected to DNA fingerprinting. HMEC were grown in MEGM/DMEM-F12 complete media (Lonza and Mediatech) at 37°C in a humidified 5% CO2–95% air atmosphere. Relative survival assays were conducted as described (15). Experiments were repeated at least 3 times, and data expressed as relative survival (treated/control × 100%) means ± SE. Results using this assay directly correlated with clonogenic assays (15). A multitarget model was used to describe the shape of relative survival curves, where the final slope (D0) and quasi-threshold (Dq) doses were used to represent the size or width of the shoulder. Three parameters, n (extrapolation number), D0, and Dq were related as: logn = Dq//D0. In experiments with catalase, bovine catalase (Sigma-Aldrich) was dissolved in 5 mmol/L Hepes buffer (pH 7.4) or PBS. Dissolved catalase was filter sterilized and added to drug media before exposure to drug treatment. O2 consumption rates (OCR) were measured using an Ocean Optics, Inc. Foxylight18G-AF oxygen sensor and S9 supernatants (15). S9 extracts were added to a closed system in Tris-HCl buffer containing 10% BSA, pH 7.5, 0.5 mmol/L NADH, β-lap ± 40 μmol/L DIC (23). The OOL Sensors program (Ocean Optics, Inc.) was used to quantify fluorescence at 599.62 nm every 512 seconds, averaging every 4 readings. Data (means ± SE) were graphed as X-fold OCR from 3 independent experiments, each conducted in triplicate. In addition to Ocean Optics experiments, OCRs were confirmed in 231-NQ+ and 231-NQ− cells using a Seahorse XF24 extracellular flux analyzer (Seahorse Biosciences) as described previously (7). Briefly 25,000 231-NQ+ or 231-NQ− cells were seeded in Seahorse 24-well microplates. Before analysis, cells were left untreated (control) or treated with 4 μmol/L β-lap with or without DIC. OCR were measured as previously described (7). Data represent means, % treated/control (%T/C), ±SE from quadruplicate assessments.

ROS, NAD+, and ATP measurements

Cellular oxidative stress was assessed by reduced/total glutathione, %GSSG content (17), and normalized to protein (24). Experiments were conducted 3 times and data...
expressed as means ± SE. ROS formation was assessed microscopically in 231 NQ+- and NQ- cells stained with DCFDA or DHE. Quantitative data obtained from digital images of at least 100 cells were analyzed using NIH ImageJ software. Changes in intracellular NAD+ levels were measured (17) and data expressed as %NAD+ (% treated/control) means ± SE for experiments conducted 3 times in triplicate.

**Comet assays**

DNA damage was assessed by alkaline comet assays, tail migration distance measured and analyzed using NIH ImageJ software (17). Comet tail lengths were measured in micrometers and mean lengths ± SE reported from 3 independent experiments conducted in triplicate.

**Apoptosis**

TUNEL assays were conducted (16) and data expressed as means ± SE from 3 separate experiments.

**Western blotting and antibodies**

Western blot analyses were conducted as described (15). α-PAR and α-γ-H2AX were used as described (17). α-PARP1 (SC-8007, 1:2,000), α-AIF (SC-5586, 1:2,000), α-tubulin (1:10,000), and α-GAPDH (SC-25778 and 32233, 1:50,000) were from Santa Cruz. Additional α-GAPDH antibodies (CB-1001, 1:50,000) and (ab-9485, 1:50,000) were purchased from Calbiochem and from Abcam, respectively. Relative PAR levels were calculated by densitometric analyses using NIH ImageJ using PARP1 loading controls. Measurements were normalized to t = 0 levels. Western blots shown were representative of separate experiments conducted at least 3 times.

**Statistics**

All experiments were repeated at least twice in triplicate. Student t tests were conducted to compare conditions and data were reported as means ± SE.

**Results**

**β-Lap-induced, NQO1-dependent O2 consumption**

NQO1-driven futile redox cycling of β-lap (Fig. 1A; ref. 15) predicted a robust OCR, with concomitant rapid and dramatic O2− and H2O2 formation. Using MDA-MB-231 TNBC cells expressing (231-NQ+) or lacking (231-NQ−) NQO1, we directly measured OCR in a closed system with an Ocean Optics O2 sensor (Fig. 1B, left). Appropriate controls using KCN and oligomycin, inhibitors of the electron transport chain, were conducted (Supplementary Fig. S2). NADH, β-lap, and NQO1 enzymatic activity were necessary components for robust futile redox cycling and elevated OCR, because DIC prevented dose-dependent, β-lap–induced OCR increases (~40-fold in 5 minutes after 15 μmol/L) in 231-NQ+ cells. Significant increases in OCR were noted in NQO1+ cells exposed to 2 μmol/L versus 1 μmol/L β-lap (Fig. 1B, left). In contrast, 231-NQ− cells showed no OCR increases after β-lap, up to 15 μmol/L (Fig. 1B, left). OCRs in 231-NQ+ cells exposed to 4 μmol/L β-lap were then confirmed...
using the Seahorse monitoring systems as previously described (7). β-Lap (4 μmol/L) exposure caused an immediate burst in OCRs that were inhibited by DIC, and dissipated over the next 100 minutes (Fig. 1B, right). NQO1-dependent OCRs were accompanied by dramatic increases in O$_2$ -/C0 and H$_2$O$_2$ (Fig. 1C and D). The absence of significant ROS in NQO1- cells strongly suggested that within the 2 to 4 hours exposure of cells to β-lap (4 μmol/L), the drug was a relatively poor substrate for one-electron oxidoreductions, mediated by b5R and p450R oxidoreductases (ref. 17; Fig. 1A). Cells exposed to DOX (5 μmol/L, 30 minutes) or H$_2$O$_2$ (200 μmol/L, 30 minutes) resulted in statistically equivalent O$_2$ -/C0 or H$_2$O$_2$ levels, respectively, in 231-NQ/C0 or 231-NQ+ cells (Fig. 1C and D), suggesting that scavenging enzymes/factors present were equivalent in these NQO1 isogenic cells.

**Lethal β-lap doses cause threshold levels of DNA damage required for PARP1 hyperactivation**

Survival responses of NQO1+ human cancer cells to increasing β-lap concentrations are rather sharp, where 1 to 1.8 μmol/L treatments for 2 to 4 hours were not lethal, but incremental increases to 2 to 3 μmol/L caused >90% cell death responses, indicated by strong TUNEL+ staining (15, 17, 21). We hypothesized that these sharp dose–responses were due not only to futile redox cycling of β-lap in NQO1+ cells expressing ~100 units of NQO1 (19), but that differences between sublethal and lethal doses of the drug were due to achieving a critical threshold level of DNA lesions (specifically base damage and SSBs) that ultimately hyperactivate PARP1. We characterized sublethal (1 μmol/L, 2 hours) and lethal (≥2 μmol/L, 2 hours) β-lap doses in 231-NQ+ cells (Fig. 2A), whereas 231-NQ− cells and normal primary human mammary epithelial cells remained nonresponsive at either dose (Fig. 2B, Supplementary Fig. S3). ROS generation over time (%GSSG formation) in 231-NQ+ cells exposed to lethal versus sublethal β-lap doses indicated no statistical differences ($P > 0.5$; Fig. 2C) between treatments; use of %GSSG as an indicator of ROS was apparently not as sensitive an endpoint to discriminate sublethal versus lethal doses of β-lap (Fig. 2C) compared to use of indicator dyes (Fig. 1C and D). Interestingly, the chemical ROS scavenger, NAC (given as pre- and cotreatments with β-lap), only partially protected cells against the lethal effects of 2, but not 3 μmol/L β-lap (Fig. 2A). However, when NQO1 levels were partially inhibited by DIC, the efficacy of NAC was dramatically improved (Supplementary Fig. S4), suggesting that NQO1-dependent redox cycling of β-lap produced ROS that could easily swamp the ROS-scavenging effects of
NAC. In contrast, only minor levels of oxidative stress were noted in 231-NQ– cells at any β-lap dose tested using GSSG assays (Fig. 2D). These data suggested that although ROS scavengers were easily overwhelmed at low β-lap doses, factors such as NAC may play significant roles in protecting cells from sublethal or LD50 doses that might be used in combination therapies (14).

Alkaline comet assays were then used to assess the extent of total DNA lesions (base damage, SSBs, and double-strand breaks) created by various β-lap doses in 231-NQ+ versus 231-NQ– cells (Fig. 3A and B). Although a sublethal 1 μmol/L β-lap dose produced significant GSSG formation (Fig. 2C), this exposure caused significantly less DNA damage versus a lethal dose (2 μmol/L an ~LD70; Fig. 3A). All lethal β-lap doses (2–6 μmol/L; Fig. 3A) caused similar saturating levels of DNA lesions, consistent with elevated and saturated oxidized GSSG levels (Fig. 2C). In contrast, β-lap treatment of 231-NQ– cells did not result in significant DNA lesions, consistent with the lack of OCR, ROS (H2O2) formation and lethality in NQO1– cells.

Exposure of 231-NQ+ cells to a nonlethal β-lap (1 μmol/L) dose did not result in measurable DNA lesions, loss of NAD+ or PAR-PARP1 formation (Fig. 3A and C). In contrast, treatment of NQO1+ cells with cytotoxic β-lap doses (>2 μmol/L) resulted in significant NAD+ pool loss (Fig. 3B) and PAR-PARP1 formation (Fig. 3C), consistent with PARP1 hyperactivation (17), and steady-state accumulation of posttranslational PAR-modified and inactivated PARP1 (PAR; Fig. 3C). Peak PAR-PARP1 formation was noted 30 minutes after 2 μmol/L β-lap, whose time to peak levels decreased with increasing doses (Fig. 3C; compare 2–6 μmol/L β-lap exposures). Interestingly, loss of intracellular NAD+ levels were similar with all lethal doses of β-lap, strongly suggesting saturated PARP1 hyperactivation at all doses (Fig. 3B).

**Catalase detoxifies β-lap–induced H2O2 formation and is cytoprotective**

Exogenous catalase (1,000 U) significantly lowered H2O2 levels in β-lap–exposed 231-NQ+ cells (Fig. 4A, left), whereas its addition had no affect on O2− formation (not shown). Similarly, exogenous CuZnSOD−dependent superoxide dismutase (CuZnSOD, 3,000 U) decreased O2− formation (Fig. 4A, right), whereas slightly increasing H2O2 levels (not shown). Forced overexpression of catalase in NQO1+ MCF-7 cells (Fig. 4B) using a CMV-driven expression vector (Open Biosystems) significantly spared NQO1+ MCF-7 cells from lethal β-lap doses (Fig. 4C), ranging from 2 to 4 μmol/L.

Similarly, exogenous catalase (>500 U) significantly protected 231-NQ+ cells from β-lap lethality (Fig. 5A), whereas the survival of β-lap–treated 231-NQ– cells were not affected by the drug, with or without catalase coadministration (Fig. 5B). Exogenous coadministration of catalase with CuZnSOD significantly decreased the effective catalase dose required to prevent β-lap-induced lethality (Fig. 5C); for example, only 125 U of catalase was required with CuZnSOD to reach the same protection as 500 U catalase alone (Fig. 5A and C, P ≤ 0.001, respectively). CuZnSOD enhanced the cytoprotective effects of all catalase doses used (Fig. 5A and C, P ≤ 0.001, respectively). Exogenous catalase did not influence the survival of β-lap–resistant 231-NQ– cells with or without CuZnSOD (Fig. 5D), because OCR and ROS formation did not occur in the absence of NQO1 (Fig. 1).

Catalase also significantly suppressed DNA damage in β-lap–exposed 231-NQ+ cells monitored by comet assays (Fig. 6A), whereas β-lap-resistant 231-NQ– cells formed no DNA lesions after β-lap treatment, with or without catalase (Fig. 6B). Consistently, catalase blocked β-lap–induced PARP1 hyperactivation (Fig. 6C, top), formation of γH2AX (Fig. 6C, bottom), NAD+ loss (Fig. 6D), downstream programmed necrosis-induced
atypical PARP1 and p53 proteolytic cleavage (Fig. 6E and Supplementary Fig. S5) and TUNEL+ responses (Fig. 6F) that are uniquely associated with NQO1 bioactivatable drug lethality.

β-Lap–induced programmed necrosis is accompanied by nuclear AIF translocation

β-Lap-treated MCF-7 cells (Supplementary Fig. S6) undergo atypical PARP1 and p53 proteolysis (15) due to μ-calpain activation (16, 25), whereas treatment of the same cells with staurosporine (STS) yielded classic apoptosis-related, ~89 kDa PARP1 proteolysis (Supplementary Fig. S6). BAPTA-AM, a calcium chelator, or DIC prevented β-lap–induced programmed necrosis. In contrast, the pan-caspase inhibitor, Z-VAD (see Supplementary Fig. S1 for structure), had no affect on β-lap–induced cell death or downstream PARP1/p53 proteolysis (Supplementary Fig. S6), but blocked STS-related PARP1 cleavage (26).

Because μ-calpain activation can stimulate downstream AIF translocation from mitochondria (9, 27), inducing programmed cell death (9), we examined a role for AIF in β-lap lethality. Indeed, activation and translocation of AIF from mitochondria (DMSO; Fig. 7A) to nuclei was noted (4–24 hours posttreatment; Fig. 7A) in β-lap–treated MCF-7 cells, consistent with μ-calpain activation kinetics (16, 25). AIF activation was blocked by BAPTA-AM (Fig. 7B) or catalase (1,000 U) cotreatments (Fig. 7C). However, siRNA-mediated AIF knockdown only partially decreased the lethal effects of β-lap in MCF-7 cells (Fig. 7D), most likely due to simultaneous activation of other cell death mediators, including posttranslational modification/activation of GAPDH (Fig. 8) that mediates apoptotic-like cell death (28). Stable AIF knockdown in MDA-MB-231 cells, like those recently reported (29), resulted in dramatic morphology and growth alterations, with similar partial blockade of lethality noted in β-lap–treated MCF-7 cells (Fig. 7D). Thus, β-lap stimulates multiple cell death factors, including μ-calpain (16, 25), AIF (Fig. 7), and S-nitrosylated GAPDH (Fig. 8).

Discussion

We used chemoresistant MDA-MB-231 TNBC cells to link NQO1-dependent futile cycling of β-lap to ROS-induced DNA damage and PARP1 hyperactivation. Threshold-level responses in cells after β-lap treatments were noted by sharp dose-dependent trigger events, mediated by robust H2O2 formation that, in turn, caused both DNA damage and Ca2+ release, ultimately leading to PARP1 hyperactivation (Supplementary Fig. S7). H2O2 production was the obligate ROS inducing cell death after β-lap, because catalase administration alone protected cells. PARP1 hyperactivation, both in dose–response and
temporal kinetics of triggering cell death, resulted in catastrophic loss of essential nucleotides (NAD\(^+\) and ATP) that correlated well with the "2 hours minimum time to death" induced by \(\beta\)-lap in NQO1\(^+\) expressing cells (17). Downstream, AIF activation and nuclear translocation (Fig. 7) were consistent with our prior findings of \(\mu\)-calpain activation (25), and previously described role(s) of \(\mu\)-calpain in AIF activation by others (30). However, AIF activation is one of a number of simultaneously activated cell death responses stimulated during \(\beta\)-lap-induced programmed necrosis, and we were not able to completely protect cells by AIF knockdown alone, as others suggested (29). Differences in AIF knockdown could explain the conflicting results, however, our identification of various cell death factors (e.g., \(\mu\)-calpain, AIF, GAPDH modification, as well as loss of essential
nucleotides) simultaneously activated in β-lap-exposed NQO1+ cells, make it unlikely that AIF abrogation alone would spare most β-lap-exposed solid cancer cells. Although not explored in detail, the posttranslational modification of GAPDH in β-lap-treated NQO1+ cells has potentially important implications for understanding β-lap-induced cell "clean-up." S-nitrosylation of GAPDH implies a potentially important role of nitric oxide species (NOS; ref. 28) in β-lap-induced lethality. GAPDH modification inhibits its functions in glycolysis (31, 32) and activates its DNA repair (33) and cell death (34) functions, suggesting dramatic metabolic changes in exposed cancer cells due to this agent. Exposure to therapeutic β-lap doses caused supra-lethal ROS levels and DNA damage that was not repaired, presumably due to loss of NAD+ /ATP within ~60 minutes of exposure (Fig. 3B). We are currently exploring the roles of NOS and posttranslational GAPDH in altered metabolism and repair in NQO1+ cells exposed to β-lap.

We present the first evidence that H2O2 is the primary obligate ROS species necessary for β-lap’s lethal effects. A primary role for H2O2 is also consistent with the specific induction of SSBS caused by this promising tumor-selective antitumor agent. CuZnSOD specifically enhanced the efficacy of catalase to block β-lap cytotoxicity in NQO1+ cancer cells. These data predict that normal tissue, which typically has higher catalase levels than cancer cells (35–37), could be selectively spared from toxicity caused by this agent. Alternatively, cancer cells overexpressing catalase and/or CuZnSOD would require higher doses of β-lap to avoid “sublethal therapeutic treatments.” Accordingly, we propose that the ratio of NQO1 to catalase expression in tumor versus normal tissue is a major determinant of tumor selectivity for β-lap and future drugs that work by “NQO1 bioactivation.” On this point, it is interesting that an inverse correlation between NQO1 expression and catalase is noted across breast cancer cells (Supplementary Fig. S8). We also noted that catalase expression in breast cancer cells was commonly low and did not dramatically affect the lethality of β-lap–treated breast cancer cells that overexpress NQO1. We predict that NQO1/catalase ratio calculations are important when examining normal tissue versus tumor tissue, but that β-lap–exposed NQO1 overexpressing cells will...
Catalase Confers Resistance to β-Lapachone Cell Death

respond whether catalase is expressed or not, since ROS production can overwhelm catalase-mediated scavenging due to the futile cycle (Fig. 1A).

Catalase protects cells from H2O2-induced lipid peroxidation that damages membranes and cellular organelles. Although exogenous catalase enhanced survival at low doses, excessive ROS and NOS formation by higher β-lap doses (>6 μmol/L) were not inhibited by catalase alone. Although CuZnSOD alone did not spare β-lap–exposed NQO1+ cells, it enhanced the cytoprotective capacity of catalase. Combining CuZnSOD with catalase presumably converted superoxide to 2H2O2 that was easily detoxified by catalase to O2- + H2O.

β-Lap-treated NQO1+ breast cancer cells, including TNBC cells, produce supra-lethal levels of ROS due to futile cycle metabolism of β-lap specifically by NQO1. The mechanism of action of this agent involves PARP1 hyperactivation that triggers simultaneous redundant downstream lethal events, including essential nucleotide loss (NAD+ and ATP), AIF release, S-nitrosylation of GAPDH, and eventually programmed necrosis. Identification of ROS-scavenging enzymes (i.e., SOD, catalase) that can partially suppress β-lap–induced lethality is a crucial step in understanding resistance factors for this agent. Interrogation of expression of these factors may allow us to predict efficacious doses required for improved efficacy of NQO1 bioactivatable drugs, such as β-lap, DNQ, and their derivatives. Because NQO1 levels are overexpressed in breast cancer versus adjacent normal tissue (11), and particularly in ER− breast cancer patients (38), these data strongly indicate use of this agent against breast, as well as many other solid tumors that specifically overexpress NQO1. Monitoring NQO1/catalase ratios in tumor versus normal tissue will be essential for “personalized therapies” using β-lap or other NQO1 bioactivatable drugs.

Disclosures of Potential Conflicts of Interest
J. Gao is a consultant/advisory board member for StemPAR Sciences, Inc. D.A. Boothman is a consultant/advisory board member for StemPAR Sciences, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: E.A. Bey, M.C. Srougi, L. Cao, Z. Moore, W.G. Bornmann, D.J. Buchsbaum, D.R. Spitz, J. Gao, D.A. Boothman
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.A. Bey, K.E. Reinicke, M.C. Srougi, L.S. Li, M. Patel, L. Cao, Z. Moore, A. Rommel, C. Lewis, D.M. Euhus, W.G. Bornmann, D.J. Buchsbaum, D.R. Spitz, D.A. Boothman
Writing, review, and/or revision of the manuscript: E.A. Bey, K.E. Reinicke, L. Cao, Z. Moore, M. Boatman, D.J. Buchsbaum, D.R. Spitz, J. Gao, D.A. Boothman
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.A. Bey, M. Varnes, L.S. Li, L. Cao, Z. Moore, M. Boatman, D.A. Boothman
Study supervision: E.A. Bey, V.E. Anderson, L. Cao, Z. Moore, D.A. Boothman

Acknowledgments
This article is dedicated to Dr. M. Varnes, Emeritus Professor of Radiation Oncology, CWRU, who began these studies. The authors also thank the imaging, mouse metabolism, and flow cytometry cores, Simmons Comprehensive Cancer Center.

Grant Support
This work was supported by NIH/NCI grant CA102792 to D.A. Boothman and DoD Breast Cancer Pre-Doctoral Fellowships to K.E. Reinicke (W81XWH-05-1-0248) and M.C. Srougi (W81XWH-04-1-0031). Grant CA13314 supported D.R. Spitz, as did CA086862, the Radiation and Free Radical Research Core. This work was also supported by a Susan G. Komen grant (K29909669) and NIH grant P30 CA086019 to D.J. Buchsbaum.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 3, 2012; revised June 24, 2013; accepted July 18, 2013; published OnlineFirst July 24, 2013.

References
3. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer patients (38), these data strongly indicate use of this agent against breast, as well as many other solid tumors that specifically overexpress NQO1. Monitoring NQO1/catalase ratios in tumor versus normal tissue will be essential for “personalized therapies” using β-lap or other NQO1 bioactivatable drugs.

Figure 8. GAPDH proteolysis is induced during β-Lap–induced cell death. MCF-7 cells were treated with β-lap (4 μmol/L, 2 hours) and whole-cell extracts monitored for PAR-PARP1, S-nitrosylated GAPDH (M-GAPDH), or total GAPDH (R-GAPDH) using antibodies that detect a specific site known to be S-nitrosylated (41) or a polyclonal antibody to GAPDH, respectively. MSH2 levels were monitored as an internal loading control.

www.aacrjournals.org Mol Cancer Ther; 12(10) October 2013 2119
Bey et al.


